Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333943 | 0.86 | CA3 (0.41) | ALDH1A1HSPB1TRPA1IDO1AGXT | |
| SCHEMBL28150210 | 0.82 | POLB (0.35) | ALDH1A1HSPB1TRPA1IDO1AGXT | |
| SCHEMBL12157430 | 0.82 | TRPA1 (0.39) | ALDH1A1HSPB1TRPA1CES2CES1 | |
| SCHEMBL1702678 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1174545 | 0.77 | ACHE (0.41) | ALDH1A1CA9 | |
| SCHEMBL1174046 | 0.77 | PPARG (0.44) | ALDH1A1 | |
| SCHEMBL3151958 | 0.77 | MAPK1 (0.41) | ALDH1A1 | |
| SCHEMBL593480 | 0.77 | SLC6A4 (0.39) | ALDH1A1 | |
| SCHEMBL2477993 | 0.77 | CA3 (0.48) | IDO1CA3CA6CA5ACA9 | |
| SCHEMBL337001 | 0.77 | SLC6A4 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106589321-B | Preparation method and applications based on cationic conjugated polymer Yu the fluorescent optical sensor system of complex of iridium FRET effect | 宁波大学 | 2019-11-12 | — | — | CN | claimed |
| CN-104530135-A | Blue-phosphorescence pyrimidine iridium complex and preparation method thereof | UNIV NINGBO | 2015-04-22 | — | — | CN | claimed |
| CN-104402936-A | Iridium complex and preparation method thereof | UNIV NINGBO | 2015-03-11 | — | — | CN | claimed |
| CN-104370973-A | Iridium complex and preparation method thereof | UNIV NINGBO | 2015-02-25 | — | — | CN | claimed |
| WO-2026107178-A1 | GLOBAL AFFINITY PROFILING OF MOLECULAR INTERACTIONS USING COMPETITIVE ENRICHMENT | CORNELL UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026099455-A1 | DIHYDROPYRROLOPYRIMIDINONE COMPOUNDS AS TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250362302-A1 | INTRACELLULAR LIGATION OF PHOTOCATALYSTS FOR PHOTO-RESPONSIVE, PROBE-MEDIATED PROTEIN LABELING | SEED THERAPEUTICS US INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0413785-B1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK PATENT GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| EP-0413785-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS. | MERCK PATENT GMBH (DE) | 1991-02-27 | — | — | EP | disclosed |
| WO-1990009420-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | ALDH1A1 1394/4885HSPB1 834/4885TRPA1 2635/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | ALDH1A1 1252/4885HSPB1 1468/4885TRPA1 72/4885 |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | ALDH1A1 232/4885HSPB1 1945/4885TRPA1 2857/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | ALDH1A1 189/4885HSPB1 1675/4885TRPA1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.